{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:57:37Z","timestamp":1790758657461,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Type 2 diabetes (T2D) is associated with a substantial burden of cardiovascular and renal complications. Although current evidence supports early implementation of organ-protective strategies, therapeutic inertia and uncertainty regarding guideline implementation may delay treatment intensification. The goal of this review is to discuss the rationale for early cardiorenal protection in T2D and to explore real-world perspectives on the use of SGLT2 inhibitors and GLP-1 receptor agonists through insights from the PRECARE NO LiMITS initiative. This narrative review integrates current evidence with exploratory findings from the PRECARE NO LiMITS project, a multicentre educational initiative involving diabetologists from ten diabetes centres in Lombardy, Italy. The initiative included two descriptive clinician survey rounds, conducted at baseline (T0) and after six months (T1), together with moderated expert discussions. At T1, a higher proportion of respondents reported considering SGLT2 inhibitor initiation in a greater proportion of patients with early cardiorenal risk markers, including albuminuria and mildly reduced eGFR, even in the absence of established cardiovascular or renal disease. Survey responses also suggested greater consideration of risk-based treatment strategies extending beyond glycaemic control alone. Persistent perceived barriers included reliance on HbA1c as a primary driver of treatment intensification, uncertainty regarding the timing and implementation of organ-protective therapies, and concerns related to treatment complexity and access. Given the descriptive nature of the survey, differences between T0 and T1 should be interpreted as exploratory. Overall, these exploratory observations, considered alongside current evidence and guideline recommendations, highlight the potential value of a proactive approach to T2D management focused on early identification of cardiorenal risk and appropriate consideration of organ-protective therapies. Educational initiatives, multidisciplinary collaboration, and improved translation of guideline recommendations into routine clinical practice may help address therapeutic inertia and facilitate timely, individualised treatment decisions.<\/jats:p>","DOI":"10.1007\/s00592-026-02798-y","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:08:20Z","timestamp":1790755700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging the gap in early cardio-renal risk prevention in type 2 diabetes: evidence, guidelines, and real-world insights from the PRECARE NO LiMITS initiative"],"prefix":"10.1007","author":[{"given":"Loredana","family":"Bucciarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Lunati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Berra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Cerutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Ghelardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Girelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Morpurgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Scaranna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Tinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1093-7724","authenticated-orcid":false,"given":"Paolo","family":"Fiorina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of PRECARE NO LiMITS study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"2798_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54989-8","volume":"14","author":"C Abbafati","year":"2024","unstructured":"Abbafati C, Nieddu L, Monasta L (2024) Measures of type 2 diabetes burden in Italy assessed using the AMD dataset over a twelve-year span across the Great Recession. Sci Rep 14:4901. https:\/\/doi.org\/10.1038\/s41598-024-54989-8","journal-title":"Sci Rep"},{"key":"2798_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.numecd.2022.01.026","volume":"32","author":"GT Russo","year":"2022","unstructured":"Russo GT, Corigliano G, Arturi F, Cavallo MG, Bette C, Mannucci E (2022) CAPTURE: a cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy. Nutr Metab Cardiovasc Dis 32:1195\u20131201. https:\/\/doi.org\/10.1016\/j.numecd.2022.01.026","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2798_CR3","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.2147\/DMSO.S319895","volume":"14","author":"J Reed","year":"2021","unstructured":"Reed J, Bain S, Kanamarlapudi V (2021) A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives. Diabetes Metab Syndr Obes 14:3567\u20133602. https:\/\/doi.org\/10.2147\/DMSO.S319895","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2798_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2337\/db24-0166","volume":"74","author":"GT Russo","year":"2025","unstructured":"Russo GT, Nicolucci A, Lucisano G, Rossi MC, Ceriello A, Prattichizzo F, Manicardi V, Rocca A, Di Bartolo P, De Cosmo S, Di Cianni G, Candido R (2025) When does metabolic memory start? Insights from the Association of Medical Diabetologists Annals Initiative on stringent HbA1c targets. Diabetes 74:75\u201381. https:\/\/doi.org\/10.2337\/db24-0166","journal-title":"Diabetes"},{"key":"2798_CR5","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577\u20131589. https:\/\/doi.org\/10.1056\/NEJMoa0806470","journal-title":"N Engl J Med"},{"issue":"10472","key":"2798_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0140-6736(24)02382-1","volume":"405","author":"F Prattichizzo","year":"2025","unstructured":"Prattichizzo F, Ceriello A (2025) The legacy effect of hyperglycaemia in type 2 diabetes. Lancet 405(10472):28. https:\/\/doi.org\/10.1016\/S0140-6736(24)02382-1","journal-title":"Lancet"},{"key":"2798_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","volume":"404","author":"AI Adler","year":"2024","unstructured":"Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR (2024) Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet 404:145\u2013155. https:\/\/doi.org\/10.1016\/S0140-6736(24)00537-3","journal-title":"Lancet"},{"key":"2798_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405\u2013412. https:\/\/doi.org\/10.1136\/bmj.321.7258.405","journal-title":"BMJ"},{"key":"2798_CR9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2337\/dc17-1144","volume":"42","author":"N Laiteerapong","year":"2019","unstructured":"Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, Karter AJ (2019) The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study). Diabetes Care 42:416\u2013426. https:\/\/doi.org\/10.2337\/dc17-1144","journal-title":"Diabetes Care"},{"key":"2798_CR10","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/eurjpc\/zwac315","volume":"30","author":"CE Lim","year":"2023","unstructured":"Lim CE, Pasternak B, Eliasson B, Danaei G, Ueda P (2023) Use of sodium\u2013glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA\/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prev Cardiol 30:634\u2013643. https:\/\/doi.org\/10.1093\/eurjpc\/zwac315","journal-title":"Eur J Prev Cardiol"},{"key":"2798_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.pcd.2025.05.005","volume":"19","author":"EE Wright","year":"2025","unstructured":"Wright EE, Cebrian A, Ngui D (2025) A primary care guide to the screening and pharmacologic management of chronic kidney disease in people living with type 2 diabetes. Prim Care Diabetes 19:411\u2013421. https:\/\/doi.org\/10.1016\/j.pcd.2025.05.005","journal-title":"Prim Care Diabetes"},{"key":"2798_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"2798_CR13","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N, ESC Scientific Document Group (2023) 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44:4043\u20134140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"key":"2798_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100847","volume":"38","author":"GP Fadini","year":"2024","unstructured":"Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A, DARWIN-Renal Study Investigators (2024) Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score-matched cohorts at low renal risk. Lancet Reg Health Eur 38:100847. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100847","journal-title":"Lancet Reg Health Eur"},{"key":"2798_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ph18081130","volume":"18","author":"SA Rabbani","year":"2025","unstructured":"Rabbani SA, El-Tanani M, Kumar R, Saini M, El-Tanani Y, Sharma S, Aljabali AAA, Hajeer E, Rizzo M (2025) Repurposing diabetes therapies in CKD: mechanistic insights, clinical outcomes and safety of SGLT2i and GLP-1 RAs. Pharmaceuticals (Basel) 18:1130. https:\/\/doi.org\/10.3390\/ph18081130","journal-title":"Pharmaceuticals (Basel)"},{"key":"2798_CR16","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-024-01550-5","volume":"15","author":"S Seidu","year":"2024","unstructured":"Seidu S, Alabraba V, Davies S, Newland-Jones P, Fernando K, Bain SC, Diggle J, Evans M, James J, Kanumilli N, Milne N, Viljoen A, Wheeler DC, Wilding JPH (2024) SGLT2 inhibitors\u2014the new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review. Diabetes Ther 15:1099\u20131124. https:\/\/doi.org\/10.1007\/s13300-024-01550-5","journal-title":"Diabetes Ther"},{"key":"2798_CR17","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00247.2003","author":"JT Lane","year":"2004","unstructured":"Lane JT (2004) Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. Am J Physiol Renal Physiol. https:\/\/doi.org\/10.1152\/ajprenal.00247.2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"2798_CR18","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2337\/dc13-1870","volume":"37","author":"GL Bakris","year":"2014","unstructured":"Bakris GL, Molitch M (2014) Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care 37:867\u2013875. https:\/\/doi.org\/10.2337\/dc13-1870","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"2798_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14007","volume":"22","author":"NM Selby","year":"2020","unstructured":"Selby NM, Taal MW (2020) An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 22(Suppl 1):3\u201315. https:\/\/doi.org\/10.1111\/dom.14007","journal-title":"Diabetes Obes Metab"},{"key":"2798_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/16089677.2022.2113206","volume":"28","author":"U Adamu","year":"2023","unstructured":"Adamu U, Mpanya D, Patel A, Tsabedze N (2023) Beyond HbA1c cardiovascular protection in type 2 diabetes mellitus. J Endocrinol Metab Diabetes S Afr 28:7\u201313. https:\/\/doi.org\/10.1080\/16089677.2022.2113206","journal-title":"J Endocrinol Metab Diabetes S Afr"},{"key":"2798_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12123925","volume":"12","author":"A Castro Conde","year":"2023","unstructured":"Castro Conde A, Marzal Mart\u00edn D, Campuzano Ruiz R, Fern\u00e1ndez Olmo MR, Morillas Ari\u00f1o C, G\u00f3mez Doblas JJ, Gorriz Teruel JL, Maz\u00f3n Ramos P, Garc\u00eda-Moll Marimon X, Soler Romeo MJ, Le\u00f3n Jim\u00e9nez D, Arrarte Esteban V, Obaya Rebollar JC, Escobar Cervantes C, Gorgojo Mart\u00ednez JJ (2023) Comprehensive cardiovascular and renal protection in patients with type 2 diabetes. J Clin Med 12:3925. https:\/\/doi.org\/10.3390\/jcm12123925","journal-title":"J Clin Med"},{"key":"2798_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02874-7","volume":"24","author":"Z Arow","year":"2025","unstructured":"Arow Z, Hornik-Lurie T, Hilu R, Giladi E, Arnson Y, Vaknin-Assa H, Assali A, Pereg D, CARDIAB Research Group (2025) SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease. Cardiovasc Diabetol 24:353. https:\/\/doi.org\/10.1186\/s12933-025-02874-7","journal-title":"Cardiovasc Diabetol"},{"key":"2798_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2024.100455","volume":"46","author":"TK Reddy","year":"2024","unstructured":"Reddy TK, Villavaso CD, Pulapaka AV, Ferdinand KC (2024) Achieving equitable access to incretin-based therapies in cardiovascular care. Am Heart J Plus 46:100455. https:\/\/doi.org\/10.1016\/j.ahjo.2024.100455","journal-title":"Am Heart J Plus"},{"key":"2798_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2337\/cd20-0053","volume":"38","author":"RA Gabbay","year":"2020","unstructured":"Gabbay RA, Kendall D, Beebe C, Cuddeback J, Hobbs T, Khan ND, Leal S, Miller E, Novak LM, Rajpathak SN, Scribner P, Meneghini L, Khunti K (2020) Addressing therapeutic inertia in 2020 and beyond: a 3-year initiative of the American Diabetes Association. Clin Diabetes 38:371\u2013381. https:\/\/doi.org\/10.2337\/cd20-0053","journal-title":"Clin Diabetes"},{"key":"2798_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2337\/ds19-0016","volume":"33","author":"NA Zhu","year":"2020","unstructured":"Zhu NA, Harris SB (2020) Therapeutic inertia in people with type 2 diabetes in primary care: a challenge that just won\u2019t go away. Diabetes Spectr 33:44\u201349. https:\/\/doi.org\/10.2337\/ds19-0016","journal-title":"Diabetes Spectr"},{"key":"2798_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107828","volume":"35","author":"FJ Ampudia-Blasco","year":"2021","unstructured":"Ampudia-Blasco FJ, Palanca A, Trillo JL, Navarro J, Real JT (2021) Therapeutic inertia in patients with type 2 diabetes treated with non-insulin agents. J Diabetes Complicat 35:107828. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107828","journal-title":"J Diabetes Complicat"},{"key":"2798_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ndt\/gfab243","volume":"38","author":"P Rossing","year":"2023","unstructured":"Rossing P (2023) HbA1c and beyond. Nephrol Dial Transplant 38:34\u201340. https:\/\/doi.org\/10.1093\/ndt\/gfab243","journal-title":"Nephrol Dial Transplant"},{"issue":"9144","key":"2798_CR28","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(98)00090-7","volume":"352","author":"CJ Bailey","year":"1998","unstructured":"Bailey CJ, Grant PJ (1998) The UK Prospective Diabetes Study. Lancet 352(9144):1932. https:\/\/doi.org\/10.1016\/S0140-6736(98)00090-7. (PMID: 9863806)","journal-title":"Lancet"},{"key":"2798_CR29","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1093\/ndt\/gfae106","volume":"39","author":"P McEwan","year":"2024","unstructured":"McEwan P, Gabb PD, Davis JA, Garcia Sanchez JJ, Sj\u00f6str\u00f6m CD, Barone S, Kashioulis P, Ouwens M, Cassimaty S, Correa-Rotter R, Rossing P, Wheeler DC, Heerspink HJL (2024) The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. Nephrol Dial Transplant 39:2040\u20132047. https:\/\/doi.org\/10.1093\/ndt\/gfae106","journal-title":"Nephrol Dial Transplant"},{"key":"2798_CR30","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s40265-024-02090-9","volume":"84","author":"AJ Scheen","year":"2024","unstructured":"Scheen AJ (2024) GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes: pleiotropic cardiometabolic effects and add-on value of a combined therapy. Drugs 84:1347\u20131364. https:\/\/doi.org\/10.1007\/s40265-024-02090-9","journal-title":"Drugs"},{"key":"2798_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/geriatrics10060144","volume":"10","author":"K Vafeidou","year":"2025","unstructured":"Vafeidou K, Psoma O, Apostolidis E, Sarvani A, Doumas M, Kotsa K, Tsimihodimos V, Koufakis T (2025) Clinical inertia in SGLT2 inhibitor use among elderly patients with type 2 diabetes and chronic kidney disease: a comparison of regional and university hospital practice. Geriatrics 10:144. https:\/\/doi.org\/10.3390\/geriatrics10060144","journal-title":"Geriatrics"},{"key":"2798_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106396","volume":"183","author":"ME Lunati","year":"2022","unstructured":"Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, Pace C, Betella N, Favacchio G, Bulgheroni M, Bucciarelli L, Massari G, Mascardi C, Girelli A, Morpurgo PS, Folli F, Luzi L, Mirani M, Pintaudi B, Bertuzzi F, Berra C, Fiorina P (2022) SGLT2 inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res 183:106396. https:\/\/doi.org\/10.1016\/j.phrs.2022.106396","journal-title":"Pharmacol Res"},{"key":"2798_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106374","volume":"183","author":"E Lazzaroni","year":"2022","unstructured":"Lazzaroni E, Lunati ME, Montefusco L, Pastore I, Chebat E, Cimino V, Morpurgo PS, Muratori M, Plebani L, Bolla A, Rossi A, Vallone L, Gandolfi A, Tinari C, D\u2019Addio F, Nasr MB, Loretelli C, Scaranna C, Bellante R, Manfrini R, Muratori F, Franzetti I, Orsi E, Gazzaruso C, Ghelardi R, Desenzani P, Genovese S, Girelli A, Folli F, Berra C, Fiorina P (2022) Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus: the PRECARE study. Pharmacol Res 183:106374. https:\/\/doi.org\/10.1016\/j.phrs.2022.106374","journal-title":"Pharmacol Res"},{"issue":"Suppl 1","key":"2798_CR34","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","volume":"48","author":"American Diabetes Association Professional Practice Committee 2","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee 2 (2025) Diagnosis and classification of diabetes: Standards of Care in Diabetes\u20142025. Diabetes Care 48(Suppl 1):S27\u2013S49. https:\/\/doi.org\/10.2337\/dc25-S002","journal-title":"Diabetes Care"},{"key":"2798_CR35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00592-023-02107-x","volume":"60","author":"E Mannucci","year":"2023","unstructured":"Mannucci E, Candido R, Delle Monache L, Gallo M, Giaccari A, Masini ML, Mazzone A, Medea G, Pintaudi B, Targher G, Trento M, Turchetti G, Lorenzoni V, Monami M, Societ\u00e0 Italiana di Diabetologia (SID), Associazione Medici Diabetologi (AMD) (2023) 2023 update on Italian guidelines for the treatment of type 2 diabetes. Acta Diabetol 60:1119\u20131151. https:\/\/doi.org\/10.1007\/s00592-023-02107-x","journal-title":"Acta Diabetol"},{"key":"2798_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-099966","author":"P Kushner","year":"2025","unstructured":"Kushner P, Mende C (2025) Screening programmes for early detection of chronic kidney disease in the USA and other English-speaking countries (Canada, Australia and UK): a systematic literature review. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2025-099966","journal-title":"BMJ Open"},{"key":"2798_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.46747\/cfp.700130","volume":"70","author":"K Hawker","year":"2024","unstructured":"Hawker K, Akter R, Molnar F, Frank C (2024) Management of type 2 diabetes in patients with frailty. Can Fam Physician 70:30\u201332. https:\/\/doi.org\/10.46747\/cfp.700130","journal-title":"Can Fam Physician"},{"key":"2798_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac201","author":"M Evans","year":"2022","unstructured":"Evans M, Morgan AR, Davies S, Beba H, Strain WD (2022) The role of sodium\u2013glucose cotransporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing. https:\/\/doi.org\/10.1093\/ageing\/afac201","journal-title":"Age Ageing"},{"key":"2798_CR39","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.2174\/0113816128347041241129055001","volume":"31","author":"FS Ragusa","year":"2025","unstructured":"Ragusa FS, Veronese N, Ciriminna S, Agnello D, Capitummino R, Cavaleri C, D\u2019Aleo A, Errera CM, Garlisi MC, Giannettino C, Nigro AL, Lampo SEM, Plano OG, Speziale G, Titone PR, Barbagallo M, Dominguez LJ (2025) Use of SGLT2 inhibitors in frail older adults is associated with increased survival: a retrospective study. Curr Pharm Des 31:1290\u20131298. https:\/\/doi.org\/10.2174\/0113816128347041241129055001","journal-title":"Curr Pharm Des"},{"issue":"Suppl 1","key":"2798_CR40","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.2337\/dc25-S013","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 13 Older adults: Standards of Care in Diabetes\u20142025. Diabetes Care 48(Suppl 1):S266\u2013S282. https:\/\/doi.org\/10.2337\/dc25-S013","journal-title":"Diabetes Care"},{"key":"2798_CR41","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jama.2016.0299","volume":"315","author":"KJ Lipska","year":"2016","unstructured":"Lipska KJ, Krumholz H, Soones T, Lee SJ (2016) Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. JAMA 315:1034\u20131045. https:\/\/doi.org\/10.1001\/jama.2016.0299","journal-title":"JAMA"},{"key":"2798_CR42","doi-asserted-by":"publisher","first-page":"263355652311659","DOI":"10.1177\/26335565231165966","volume":"13","author":"JD Andersen","year":"2023","unstructured":"Andersen JD, Jensen MH, Vestergaard P, Jensen V, Hejlesen O, Hangaard S (2023) The multidisciplinary team in diagnosing and treatment of patients with diabetes and comorbidities: a scoping review. J Multimorb Comorb 13:26335565231165970. https:\/\/doi.org\/10.1177\/26335565231165966","journal-title":"J Multimorb Comorb"},{"key":"2798_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae331","author":"G Ev\u00e9n","year":"2024","unstructured":"Ev\u00e9n G, Stenfors T, Jacobson SH, Jernberg T, Franz\u00e9n-Dahlin \u00c5, J\u00e4ghult S, Kahan T, Spaak J (2024) Integrated, person-centred care for patients with complex cardiovascular disease, diabetes mellitus and chronic kidney disease: a randomized trial. Clin Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfae331","journal-title":"Clin Kidney J"},{"key":"2798_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5334\/ijic.6025","volume":"22","author":"R Zarora","year":"2022","unstructured":"Zarora R, Immanuel J, Chivese T, MacMillan F, Simmons D (2022) Effectiveness of integrated diabetes care interventions involving diabetes specialists working in primary and community care settings: a systematic review and meta-analysis. Int J Integr Care 22:11. https:\/\/doi.org\/10.5334\/ijic.6025","journal-title":"Int J Integr Care"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02798-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02798-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02798-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:08:21Z","timestamp":1790755701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-026-02798-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":44,"alternative-id":["2798"],"URL":"https:\/\/doi.org\/10.1007\/s00592-026-02798-y","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PF has received honoraria or lecture\/consultancy fees from Astra Zeneca, Boehringer, Lilly, Merk-Sharpe-Dome, Novonordisk, Sanofi. LB has received honoraria or lecture\/consultancy fees from Astra Zeneca, Boehringer, Lilly, Abbott, Savio, Guidotti, Dexcom, Novonordisk and Sanofi. AR has received honoraria for speaking and\/or consulting fees from Roche Diabetes Care, Abbott Diabetes Care,\u00a0Sanofi srl. CB state honoraria for advisory boards from Eli Lilly, NovoNordisk, for consultant from Eli Lilly, NovoNordisk Aurora, for lectures, presentations, or educational events from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, NovoNordisk, for research Support from NovoNordisk Eli Lilly, and for receipt of Medical Writing or Support for Statistical Analysis from Eli Lilly, NovoNordisk. CS declares honoraria from Astrazeneca, Novonordisk, Boehringer Ingelheim, Lilly. CT, NC, MEL, AC, AG, RG, PM state no conflict of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}